World Health Organization Raises Warning Over Critical Shortage of Weight-Loss Jabs
Fewer than one in 10 individuals who could benefit from GLP-1 drugs like Wegovy are able to get them, warns the global health agency as it issues its first recommendations on the medications.
Considering in excess of 1,000,000,000 people worldwide currently classified as obese, it is calling for broader and more equitable access to GLP-1 medication.
Per forecasts, over two billion are projected to be obese by 2030 unless action is taken.
"Our latest guidance affirms that excess weight is a long-term condition that can be treated with holistic and continuous treatment," stated its chief Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and distribution challenges are major obstacles to broad access to the treatments that can aid individuals in losing significant weight, explains the body.
Skinny Jab Scarcity
Even in the present best projected scenario, the manufacturing of these medications could only cover about 100 million people – less than 10% of the global need, as stated by the WHO.
The guideline calls on countries and companies to widen availability, via strategies such as licensing agreements.
The intellectual property rights on the active ingredient – the core ingredient of Novo Nordisk's Wegovy – is due to expire in multiple nations in 2026.
The Way Obesity Injections Operate
The injections mimick a natural hormone to delay gastric emptying, curb appetite and increase satiety so individuals eat less.
Individuals usually see weight reduction in the initial weeks of starting on the regular doses.
Evidence indicates users may see weight return within a year of stopping the drug, because their typical appetite return.
Being carrying excess weight increases your risk for contracting health problems, such as diabetes, cardiovascular issues, brain attack, and certain cancers.
Obesity concerns individuals in every country and was responsible for 3.7 million deaths worldwide in 2024, according to the health agency.
